---
document_datetime: 2023-09-21 18:54:08
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/rixathon-epar-all-authorised-presentations_en.pdf
document_name: rixathon-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.0231369
conversion_datetime: 2025-12-28 01:54:38.752961
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EMA Number       | (Invented) name   | Strength   | Pharmaceutical Form                   | Route of Administration   | Immediate Packaging   | Content          | Pack size   |
|------------------|-------------------|------------|---------------------------------------|---------------------------|-----------------------|------------------|-------------|
|                  |                   |            |                                       |                           |                       | (concentration)  |             |
| EU/1/17/1185/001 | Rixathon          | 100 mg     | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 10 ml (10 mg/ml) | 2 vials     |
| EU/1/17/1185/002 | Rixathon          | 100 mg     | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 10 ml (10 mg/ml) | 3 vials     |
| EU/1/17/1185/003 | Rixathon          | 500 mg     | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 50 ml (10 mg/ml) | 1 vial      |
| EU/1/17/1185/004 | Rixathon          | 500 mg     | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 50 ml (10 mg/ml) | 2 vials     |